MA41999A - Compositions d'acide obéticholique et procédés d'utilisation - Google Patents

Compositions d'acide obéticholique et procédés d'utilisation

Info

Publication number
MA41999A
MA41999A MA041999A MA41999A MA41999A MA 41999 A MA41999 A MA 41999A MA 041999 A MA041999 A MA 041999A MA 41999 A MA41999 A MA 41999A MA 41999 A MA41999 A MA 41999A
Authority
MA
Morocco
Prior art keywords
methods
acid compositions
obeticholic acid
obeticholic
compositions
Prior art date
Application number
MA041999A
Other languages
English (en)
Inventor
Jeffrey Edwards
Lise Eliot
Roya Hooshmand-Rad
Masashi Kagihiro
Richard G Lancaster
Leigh A Macconell
Tonya K Marmon
Mitsuhiro Matono
Kay K Olmstead
Richard Pencek
Mark Pruzanski
Cathi Sciacca
David Shapiro
Ikuko Taoka
Original Assignee
Intercept Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41999(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd filed Critical Intercept Pharmaceuticals Inc
Publication of MA41999A publication Critical patent/MA41999A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041999A 2015-04-27 2016-04-26 Compositions d'acide obéticholique et procédés d'utilisation MA41999A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153040P 2015-04-27 2015-04-27
US201662317933P 2016-04-04 2016-04-04

Publications (1)

Publication Number Publication Date
MA41999A true MA41999A (fr) 2018-03-07

Family

ID=57198868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041999A MA41999A (fr) 2015-04-27 2016-04-26 Compositions d'acide obéticholique et procédés d'utilisation

Country Status (25)

Country Link
US (9) US10052337B2 (fr)
EP (3) EP4371616A3 (fr)
JP (2) JP6941057B2 (fr)
KR (1) KR20170140325A (fr)
CN (1) CN107531742A (fr)
AU (2) AU2016255045B2 (fr)
BR (1) BR112017023161A2 (fr)
CA (1) CA2983609C (fr)
CL (1) CL2017002727A1 (fr)
CO (1) CO2017011535A2 (fr)
CR (1) CR20170492A (fr)
EA (1) EA201792354A1 (fr)
EC (1) ECSP17078433A (fr)
IL (2) IL294575A (fr)
MA (1) MA41999A (fr)
MX (1) MX2017013805A (fr)
NI (1) NI201700128A (fr)
PE (1) PE20180690A1 (fr)
PH (1) PH12017501956A1 (fr)
SG (2) SG11201708606VA (fr)
SV (1) SV2017005555A (fr)
TN (1) TN2017000452A1 (fr)
TW (1) TWI723017B (fr)
WO (1) WO2016176208A1 (fr)
ZA (1) ZA201707981B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (fr) 2010-05-06 2011-11-10 Children's Hospital Medical Center Procédés et systèmes de conversion de cellules précurseurs en tissus intestinaux par différenciation dirigée
EP3712254A1 (fr) 2014-05-28 2020-09-23 Children's Hospital Medical Center Procédés et systèmes de conversion de cellules précurseurs dans des tissus gastriques à travers la différenciation dirigée
CA2963704A1 (fr) 2014-10-17 2016-04-21 Children's Hospital Medical Center Modele in vivo d'intestin grele humain faisant intervenir des cellules souches pluripotentes et ses procedes de fabrication et d'utilisation
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
KR20180125573A (ko) * 2016-03-31 2018-11-23 인터셉트 파마슈티컬즈, 인크. 유효 성분의 화학적 안정성이 뛰어난 필름 코팅정
WO2017180577A1 (fr) * 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Procédés de traitement du cancer
EP4177335A1 (fr) 2016-05-05 2023-05-10 Children's Hospital Medical Center Procédés de fabrication in vitro de tissu de fundus d'estomac et compositions associées à celui-ci
MX2018016400A (es) * 2016-06-29 2019-09-02 Menlo Therapeutics Inc Uso de antagonistas de neuroquinina 1 para tratar una variedad de afecciones pruríticas.
SG11201903697WA (en) * 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
CN108072729A (zh) * 2016-11-18 2018-05-25 华北制药集团新药研究开发有限责任公司 一种测定奥贝胆酸片溶出度的方法
EP3548507A4 (fr) 2016-12-05 2020-07-15 Children's Hospital Medical Center Organoïdes du côlon et leurs procédés de préparation et d'utilisation
CN108614038B (zh) * 2016-12-13 2022-05-17 亚宝药业集团股份有限公司 一种测定奥贝胆酸原料药有关物质的方法
CN106645497A (zh) * 2017-01-03 2017-05-10 山东省药学科学院 一种奥贝胆酸及其制剂中有关物质的检测方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
EP3609997A4 (fr) 2017-04-14 2021-03-03 Children's Hospital Medical Center Compositions de cellules souches issues de multiples cellules donneuses et leurs procédés de préparation
MX2020000873A (es) * 2017-07-24 2020-07-22 Intercept Pharmaceuticals Inc Derivados de ácidos biliares marcados isotópicamente.
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
WO2019106043A1 (fr) * 2017-11-29 2019-06-06 Hexal Ag Composition pharmaceutique comprenant de l'acide obéticholique
EP3727394A4 (fr) 2017-12-21 2021-09-08 Children's Hospital Medical Center Organoïdes humains numérisés et méthodes d'utilisation de ceux-ci
CN108572251B (zh) * 2018-05-31 2020-01-17 中国科学院昆明动物研究所 肝硬化早期小分子标志物及其应用
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
CA3117966A1 (fr) * 2018-11-08 2020-05-14 Intercept Pharmaceuticals, Inc. Methodes d'utilisation d'acide obeticholique
CN109432431B (zh) * 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
CN109655571B (zh) * 2019-01-08 2021-07-13 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的高效液相色谱分析方法
CN109620812B (zh) * 2019-01-16 2023-07-21 浙江华海药业股份有限公司 一种奥贝胆酸组合物的制备方法
WO2020160371A1 (fr) 2019-02-01 2020-08-06 The University Of Hong Kong Compositions d'organoïdes innervés et leurs procédés de fabrication
EP3946359A1 (fr) * 2019-03-26 2022-02-09 Intercept Pharmaceuticals, Inc. Méthodes de diagnostic et de traitement de maladies du foie à l'aide d'acide obéticholique
WO2020198576A1 (fr) * 2019-03-28 2020-10-01 The Board Of Trustees Of The University Of Illinois Procédés de modulation de lymphocytes t régulateurs
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
CA3141814A1 (fr) 2019-05-31 2020-12-03 Children's Hospital Medical Center Compositions organoides faconnees et leurs procedes de fabrication
EP4041233A1 (fr) * 2019-09-30 2022-08-17 Novartis AG Traitement comprenant l'utilisation d'agonistes de fxr
WO2021176430A1 (fr) * 2020-03-06 2021-09-10 Актив Трєнд Лимитєд Application d'un groupe de marqueurs pour le diagnostic et la modification de traitement de la cholangite biliaire primitive, composition pharmaceutique, et forme posologique solide pour le traitement de la cholangite biliaire primitive
CN115856110B (zh) * 2020-04-23 2025-03-04 江西科睿药业有限公司 一种3α,7α-二羟基-6α-乙基-5β-胆烷-24-醛的高效液相色谱检测方法
US20230201222A1 (en) * 2020-05-13 2023-06-29 Children's Hospital Medical Center Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN111812264B (zh) * 2020-07-09 2021-06-15 苏州旭辉检测有限公司 一种去氧胆酸类化合物的生物样品分析方法
WO2022051321A1 (fr) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Combinaisons de doses fixes de chs-131 et d'un agoniste de fxr
WO2022076683A1 (fr) * 2020-10-07 2022-04-14 Intercept Pharmaceuticals, Inc. Méthodes de traitement d'une infection à coronavirus à l'aide d'acide obéticholique
CN113143950B (zh) * 2021-05-17 2023-04-18 河北医科大学第二医院 一种治疗肝病的药物组合物及其应用
WO2023147141A1 (fr) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Polythérapie
WO2023181077A1 (fr) * 2022-03-24 2023-09-28 Zenvision Pharma Llp Composition liquide stable comprenant de l'acide obéticholique ou des sels de celui-ci
US12343351B2 (en) 2022-03-25 2025-07-01 Rutgers, The State University Of New Jersey Pulmonary function treatment
IL315941A (en) * 2022-04-21 2024-11-01 Intercept Pharmaceuticals Inc Uses of farnesoid x receptor agonists
WO2024043842A1 (fr) * 2022-08-22 2024-02-29 Pharmactive Ilac Sanayi Ve Ticaret A.S. Compositions pharmaceutiques comprenant de l'acide chénodésoxycholique (cdca) en tant que principe actif et d'autres excipients pertinents
WO2024104960A1 (fr) 2022-11-15 2024-05-23 Synthon B.V. Formulation stable comprenant de l'acide obéticholique

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ZA876640B (en) 1986-09-26 1988-03-08 Warner-Lambert Company Treated lipid regulator
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
ATE303399T1 (de) * 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
KR100943309B1 (ko) 2001-06-14 2010-02-23 오츠카 세이야쿠 가부시키가이샤 의약 조성물
US6933380B2 (en) 2001-10-19 2005-08-23 Yung-Zip Chemical Ind. Co., Ltd. Excipients containing low residual solvent and method for producing the same
BR0312426A (pt) 2002-07-03 2005-12-06 Esperion Therapeutics Inc Composição farmacêutica, métodos para tratar, prevenir ou controlar um colesterol, dislipidemia ou distúrbio relacionado, para reduzir ou evitar um efeito adverso associado com monoterapia de pantetina e para reduzir ou evitar um efeito adverso associado com monoterapia de segundo agente ativo, e, kit
US20050101505A1 (en) * 2003-11-06 2005-05-12 Daniel Wood Liquid laundry detergent composition having improved color-care properties
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2007008480A1 (fr) 2005-07-07 2007-01-18 Nanotherapeutics, Inc. Procédé servant à broyer et à préparer des poudres et compositions produites par celui-ci
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
RU2011139643A (ru) * 2009-03-17 2013-04-27 Акскан Фарма, Инк. Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
NZ595902A (en) 2009-04-24 2014-10-31 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
BR112012026843A2 (pt) 2010-04-20 2016-07-12 Cipla Ltd composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
PT3336097T (pt) 2012-06-19 2020-10-29 Intercept Pharmaceuticals Inc Preparação da forma não cristalina de ácido obeticólico
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
CA2904129A1 (fr) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions et methodes de traitement de la steatohepatite non alcoolique
CA2912139C (fr) 2013-05-14 2021-04-20 Roberto Pellicciari Derives 11-hydroxyle d'acides biliaires et leurs conjugues d'acides amines en tant que modulateurs du recepteur de farnesoide x
PL3043865T3 (pl) * 2013-09-11 2021-07-05 Institut National De La Santé Et De La Recherche Médicale (Inserm) SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B
CN105801653B (zh) 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso

Also Published As

Publication number Publication date
TWI723017B (zh) 2021-04-01
US10052337B2 (en) 2018-08-21
US20200171053A1 (en) 2020-06-04
ZA201707981B (en) 2019-03-27
EP3971199A1 (fr) 2022-03-23
EP4371616A2 (fr) 2024-05-22
US20170035784A1 (en) 2017-02-09
TW201703773A (zh) 2017-02-01
US20200046735A1 (en) 2020-02-13
CN107531742A (zh) 2018-01-02
MX2017013805A (es) 2018-09-06
CO2017011535A2 (es) 2018-01-31
CA2983609A1 (fr) 2016-11-03
SG11201708606VA (en) 2017-11-29
BR112017023161A2 (pt) 2018-07-24
JP2021183651A (ja) 2021-12-02
IL294575A (en) 2022-09-01
KR20170140325A (ko) 2017-12-20
AU2020205315A1 (en) 2020-08-06
CA2983609C (fr) 2024-05-07
EP4371616A3 (fr) 2024-08-28
AU2016255045B2 (en) 2020-04-16
US20260000682A1 (en) 2026-01-01
TN2017000452A1 (en) 2019-04-12
SG10202003110PA (en) 2020-05-28
SV2017005555A (es) 2019-01-18
US20190076446A1 (en) 2019-03-14
US20190255071A1 (en) 2019-08-22
PH12017501956A1 (en) 2018-03-26
US10646499B2 (en) 2020-05-12
US20220133745A1 (en) 2022-05-05
CR20170492A (es) 2018-05-15
EP3288958A1 (fr) 2018-03-07
EP3288958A4 (fr) 2018-09-26
US20200046736A1 (en) 2020-02-13
EA201792354A1 (ru) 2018-03-30
JP2018514534A (ja) 2018-06-07
IL255269B (en) 2022-08-01
CL2017002727A1 (es) 2018-04-27
PE20180690A1 (es) 2018-04-23
US20200054650A1 (en) 2020-02-20
ECSP17078433A (es) 2018-02-28
NI201700128A (es) 2018-04-11
JP6941057B2 (ja) 2021-09-29
IL255269A (en) 2018-02-28
WO2016176208A1 (fr) 2016-11-03
AU2016255045A1 (en) 2017-11-09
US10751349B2 (en) 2020-08-25
US10758549B2 (en) 2020-09-01

Similar Documents

Publication Publication Date Title
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
EP3414321A4 (fr) Compositions améliorant vcn et procédés d'utilisation desdites compositions
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3303634A4 (fr) Variants de cas9 et procédés d'utilisation associés
EP3313404A4 (fr) Compositions thérapeutiques, associations et procédés d'utilisation
EP3298168A4 (fr) Agents réducteurs stabilisés et leurs procédés d'utilisation
EP3341017A4 (fr) Compositions d'immunomodulation et leurs procédés d'utilisation
MA41558A (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP2964235A4 (fr) Compositions antimicrobiennes-antibiofilm et leurs procédés d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3386927A4 (fr) Compositions polymères et procédés d'utilisation
EP3377615A4 (fr) Compositions d'induction d'haploïdes et procédés d'utilisation associés
EP2996694A4 (fr) Compositions de cénicriviroc et leurs procédés de fabrication et d'utilisation
EP3478277A4 (fr) Compositions anti-acné et procédés d'utilisation
MA46044A (fr) Compositions de nettoyage comprenant un acide aminé et leurs procédés d'utilisation
EP3490569A4 (fr) Compositions topiques et ses procédés d'utilisation
EP3113613A4 (fr) Compositions d'ester de choline de l'acide lipoïque et procédés d'utilisation correspondants
EP3390676A4 (fr) Adjuvants de lixiviation et leurs procédés d'utilisation